- Home
- LLYVA vs DVA Comparison
LLYVA vs DVA Comparison
Compare LLYVA & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVA
- DVA
- Stock Information
- Founded
- LLYVA 1991
- DVA 1994
- Country
- LLYVA United States
- DVA United States
- Employees
- LLYVA N/A
- DVA N/A
- Industry
- LLYVA Broadcasting
- DVA Misc Health and Biotechnology Services
- Sector
- LLYVA Industrials
- DVA Health Care
- Exchange
- LLYVA Nasdaq
- DVA Nasdaq
- Market Cap
- LLYVA 8.3B
- DVA 9.4B
- IPO Year
- LLYVA N/A
- DVA 1995
- Fundamental
- Price
- LLYVA $80.42
- DVA $120.03
- Analyst Decision
- LLYVA
- DVA Hold
- Analyst Count
- LLYVA 0
- DVA 4
- Target Price
- LLYVA N/A
- DVA $145.00
- AVG Volume (30 Days)
- LLYVA 130.7K
- DVA 957.9K
- Earning Date
- LLYVA 01-01-0001
- DVA 10-29-2025
- Dividend Yield
- LLYVA N/A
- DVA N/A
- EPS Growth
- LLYVA N/A
- DVA 5.63
- EPS
- LLYVA N/A
- DVA 9.76
- Revenue
- LLYVA N/A
- DVA $13,317,965,000.00
- Revenue This Year
- LLYVA N/A
- DVA $6.24
- Revenue Next Year
- LLYVA $10.89
- DVA $3.32
- P/E Ratio
- LLYVA N/A
- DVA $12.45
- Revenue Growth
- LLYVA N/A
- DVA 5.14
- 52 Week Low
- LLYVA $59.45
- DVA $115.39
- 52 Week High
- LLYVA $99.63
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- LLYVA 30.70
- DVA 39.94
- Support Level
- LLYVA $79.49
- DVA $118.75
- Resistance Level
- LLYVA $84.89
- DVA $125.68
- Average True Range (ATR)
- LLYVA 2.22
- DVA 3.56
- MACD
- LLYVA -0.51
- DVA 0.14
- Stochastic Oscillator
- LLYVA 1.37
- DVA 31.04
About LLYVA Liberty Media Corporation Series A Liberty Live
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.